Intranasal ipratropium in the treatment of vasomotor rhinitis.
Ipratropium administered in the form of a nasal spray was compared with placebo in 30 patients with vasomotor rhinitis in a double-blind cross-over trial. There was a significant reduction in nasal hypersecretion during ipratropium treatment, but no effect on nasal blockage, sneezing or tickling. On the whole, 20 patients (66.7%) considered ipratropium worth using. 11 patients had mild side- effects, mainly nasal irritation, during ipratropium treatment and 7 with placebo. A therapeutical trial with ipratropium is appropriate in the management of severe rhinorrhoea in patients with vasomotor rhinitis.
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000368:Aged; D001286:Atropine Derivatives / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage*; D008875:Middle Aged; D009297:Nasal Mucosa / Q000378:metabolism; D012223:Rhinitis, Vasomotor / Q000188:drug therapy* / Q000503:physiopathology; D012912:Sneezing / Q000187:drug effects
D001286:Atropine Derivatives; D009241:Ipratropium